ArticleJournal of Korean medical science2025
Risk for Human Papillomavirus-Associated Gynecologic Cancers Among Women of Childbearing Age With Rheumatic Diseases: A Population-Based Cohort Study.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study evaluated the risk of human papillomavirus (HPV)-associated gynecologic cancers in women with rheumatic diseases (RD) during their childbearing years.
methodsUsing the Korean National Health Insurance Service-National Health Information Database (2011-2021), we conducted a cohort study of 40,514 women with RD and 199,366 women without RD aged 20-49 years. The RD cohort included 9,932 women with systemic lupus erythematosus (SLE), 23,731 with seropositive rheumatoid arthritis (SPRA), and 6,851 with ankylosing spondylitis (AS). Incidence rates and hazard ratios (HRs) for HPV-associated gynecologic cancers, including cervical intraepithelial neoplasia grade 3, and cervical, vaginal, and vulva cancers, were estimated using Cox regression.
resultsOver the mean (standard deviation) follow-up period of 67.5 (37.7) months, the incidence rate of HPV-associated gynecologic cancers was 111.5/100,000 person-years in the RD cohort and 73.2/100,000 person-years in the non-RD cohort. The incidence rate/100,000 person-years of HPV-associated gynecologic cancers in the RD subcohorts was higher in SLE (223.6) and SPRA (83.1) and lower in AS (69.1) than in the non-RD cohort. The fully adjusted HR for HPV-associated gynecologic cancers was higher in the RD cohort (HR, 2.95; 95% confidence interval [CI], 2.44-3.57) and all the RD subcohorts (SLE: HR, 1.85; 95% CI, 1.33-2.57, SPRA: HR, 4.10; 95% CI, 3.03-5.55, and AS: HR, 1.91; 95% CI, 1.06-3.43). After adjusting for comorbidities and medication use, hazard ratios increased in SPRA and AS but decreased in SLE.
conclusionKorean women of childbearing age with RD have a threefold increased risk for HPV-associated gynecologic cancers compared with those without RD. Comorbidities and medication use in SLE may influence the risk. Improved screening strategies are needed for these women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.